

Eylea (aflibercept)

Override(s)	Approval Duration
Prior Authorization	1 year

Medications	Dosing Limit
Eylea (aflibercept) 2mg vial & syringe	<p><u>Diabetic macular edema, diabetic retinopathy, neovascular “wet” age-related macular degeneration, retinal vein occlusion:</u> 2 mg per eye; each eye may be treated as frequently as every 4 weeks</p> <p><u>Retinopathy of prematurity:</u> 0.4 mg per eye; each eye may be treated as frequently as every 10 days</p>

APPROVAL CRITERIA

Requests for Eylea (aflibercept) may be approved if the following criteria are met:

- I. Individual has a diagnosis of one of the following:
 - A. Diabetic macular edema (DME) (including DME with diabetic retinopathy of any severity); **OR**
 - B. Proliferative or moderate to severe non-proliferative diabetic retinopathy with or without diabetic macular edema; **OR**
 - C. Established neovascular “wet” age-related macular degeneration; **OR**
 - D. Macular edema from branch retinal vein occlusion; **OR**
 - E. Macular edema from central retinal vein occlusion **OR**
 - F. Retinopathy of prematurity.

Requests for intravitreal injections Eylea (aflibercept) may not be approved when the above criteria are not met and for all other indications.

Key References:

1. American Academy of Ophthalmology. Preferred Practice Pattern Guidelines: Retinal Vein Occlusions. October 2019. Available at: <https://www.aao.org/preferred-practice-pattern/retinal-vein-occlusions-ppp>.
2. American Academy of Ophthalmology. Preferred Practice Pattern Guidelines: Age-Related Macular Degeneration. October 2019. Available at: <https://www.aao.org/preferred-practice-pattern/age-related-macular-degeneration-ppp>.
3. American Academy of Ophthalmology. Preferred Practice Pattern Guidelines: Diabetic Retinopathy. October 2019. Available at: <https://www.aao.org/preferred-practice-pattern/diabetic-retinopathy-ppp>.

4. Clinical Pharmacology [database online]. Tampa, FL: Gold Standard, Inc.: 2023. URL: <http://www.clinicalpharmacology.com>. Updated periodically.
5. DailyMed. Package inserts. U.S. National Library of Medicine, National Institutes of Health website. <http://dailymed.nlm.nih.gov/dailymed/about.cfm>.
6. DrugPoints® System [electronic version]. Truven Health Analytics, Greenwood Village, CO. Updated periodically.
7. Lexi-Comp ONLINE™ with AHFS™, Hudson, Ohio: Lexi-Comp, Inc.; 2023; Updated periodically.
8. [Sankar MJ, Sankar J, Chandra P. Anti-vascular endothelial growth factor \(VEGF\) drugs for treatment of retinopathy of prematurity. Cochrane Database Syst Rev 2018; 1:CD009734.](#)
9. Pulido JS, Flaxel CJ, Adelman RA, Hyman L, Folk JC, Olsen TW. American Academy of Ophthalmology: Retinal Vein Occlusions Preferred Practice Pattern® guidelines. *Ophthalmology*. 2016; 123: 182–208.
10. Stahl A, Sukgen EA, Wu WC, et al. Effect of Intravitreal Aflibercept vs Laser Photocoagulation on Treatment Success of Retinopathy of Prematurity: The FIREFLEYE Randomized Clinical Trial. *JAMA*. 2022 Jul 26;328(4):348-359. Available at: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9327573/>

Federal and state laws or requirements, contract language, and Plan utilization management programs or policies may take precedence over the application of this clinical criteria.

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from the health plan.